A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine.
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Carbon dioxide (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Soleno Therapeutics
- 09 Apr 2013 Planned end date changed from 1 Sep 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 09 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Jun 2012 Actual initiation date (Jan 2012) added as reported by ClinicalTrials.gov.